In addition, strains were derived from prototrophic strains with improved characteristics for HCDC, i.e. strains with reduced accumulation of detrimental by-products and strains with improved folding characteristics for recombinant proteins. This new accessory uses signals from luciferases synthesized in the cells if recombinant proteins accumulate in misfolded state. Fed-batch strategies to prevent misfolding are outlined below. In addition, bispecific miniantibodies with the potential to couple EGF-R overexpressing tumor cells with cells of the CD2 lymphocyte activation pathway have been obtained. Furthermore, scFv were derived from monoclonal eukaryotic cell lines applying the recombinant antibody phage display technology for present projects.
Retinoic acid is such a tumor drug.
First results indicate selective binding properties of different scFv in dependence of the tumor progression. The above mentioned scFv are also used as tools for atomic force microscopy. Therefore, these scFv might be further developed to tools for screening of natural products interacting with the respective signal pathways. BMP2 binds as extracellular ligand to its membraneous BMP-receptor inducing a signal pathway which finally lead to regeneration of bone tissue. Functional BMP2 consists of two identical monomers.